Kura Oncology (NASDAQ:KURA - Get Free Report)'s stock had its "market outperform" rating reissued by research analysts at JMP Securities in a note issued to investors on Tuesday,Benzinga reports. They currently have a $28.00 price objective on the stock. JMP Securities' target price would indicate a potential upside of 330.37% from the stock's current price.
KURA has been the topic of several other reports. Cantor Fitzgerald upgraded shares of Kura Oncology to a "strong-buy" rating in a research report on Tuesday, March 4th. StockNews.com upgraded shares of Kura Oncology from a "hold" rating to a "buy" rating in a report on Friday, April 4th. HC Wainwright restated a "buy" rating and issued a $40.00 price objective on shares of Kura Oncology in a report on Monday. BTIG Research downgraded Kura Oncology from a "buy" rating to a "neutral" rating in a report on Thursday, February 6th. Finally, Scotiabank decreased their price target on Kura Oncology from $18.00 to $10.00 and set a "sector perform" rating for the company in a research note on Wednesday, January 8th. Three investment analysts have rated the stock with a hold rating, eight have issued a buy rating and two have given a strong buy rating to the stock. Based on data from MarketBeat.com, the stock presently has an average rating of "Moderate Buy" and a consensus target price of $25.50.
Check Out Our Latest Stock Analysis on Kura Oncology
Kura Oncology Price Performance
KURA traded down $0.00 on Tuesday, hitting $6.51. 300,808 shares of the stock were exchanged, compared to its average volume of 1,144,952. The business has a 50-day moving average of $6.85 and a two-hundred day moving average of $9.85. The firm has a market capitalization of $525.54 million, a price-to-earnings ratio of -2.76 and a beta of 0.83. The company has a debt-to-equity ratio of 0.02, a current ratio of 11.47 and a quick ratio of 11.47. Kura Oncology has a 12 month low of $5.41 and a 12 month high of $23.48.
Kura Oncology (NASDAQ:KURA - Get Free Report) last posted its quarterly earnings results on Wednesday, February 26th. The company reported ($0.22) EPS for the quarter, topping analysts' consensus estimates of ($0.65) by $0.43. The business had revenue of $53.88 million for the quarter, compared to analyst estimates of $57.96 million. Sell-side analysts forecast that Kura Oncology will post -2.44 EPS for the current fiscal year.
Institutional Investors Weigh In On Kura Oncology
Institutional investors and hedge funds have recently bought and sold shares of the stock. RA Capital Management L.P. purchased a new position in Kura Oncology during the fourth quarter worth about $38,769,000. Millennium Management LLC boosted its position in Kura Oncology by 180.1% in the fourth quarter. Millennium Management LLC now owns 2,367,148 shares of the company's stock worth $20,618,000 after purchasing an additional 1,521,954 shares during the last quarter. Jacobs Levy Equity Management Inc. bought a new position in Kura Oncology in the 4th quarter valued at $8,518,000. Marshall Wace LLP bought a new stake in shares of Kura Oncology during the 4th quarter worth $8,265,000. Finally, D. E. Shaw & Co. Inc. boosted its holdings in shares of Kura Oncology by 172.0% in the 4th quarter. D. E. Shaw & Co. Inc. now owns 1,151,195 shares of the company's stock worth $10,027,000 after buying an additional 727,987 shares during the last quarter.
About Kura Oncology
(
Get Free Report)
Kura Oncology, Inc, a clinical-stage biopharmaceutical company, develops medicines for the treatment of cancer. The company's pipeline consists of small molecule product candidates that target cancer. Its lead product candidates are ziftomenib, an orally bioavailable small molecule inhibitor of the menin-KMT2A interaction for the treatment of genetically defined subsets of acute leukemias, including acute myeloid leukemia and acute lymphoblastic leukemia; tipifarnib, an orally bioavailable farnesyl transferase inhibitor combination with alpelisib for patients with PIK3CA-dependent HNSCC; and KO-2806, a farnesyl transferase inhibitor for the treatment of solid tumors.
Featured Stories
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.
Before you consider Kura Oncology, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Kura Oncology wasn't on the list.
While Kura Oncology currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Nuclear energy stocks are roaring. It's the hottest energy sector of the year. Cameco Corp, Paladin Energy, and BWX Technologies were all up more than 40% in 2024. The biggest market moves could still be ahead of us, and there are seven nuclear energy stocks that could rise much higher in the next several months. To unlock these tickers, enter your email address below.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
